B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 1.342 NOK -4.14% Market Closed
Market Cap: 52.5m NOK

Net Margin
Bergenbio ASA

-16 424.8%
Current
-45 652%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-16 424.8%
=
Net Income
-139.3m
/
Revenue
848k

Net Margin Across Competitors

Country Company Market Cap Net
Margin
NO
Bergenbio ASA
OSE:BGBIO
52.5m NOK
-16 425%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
329.8B USD
7%
US
Amgen Inc
NASDAQ:AMGN
150.6B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
133.3B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
116.2B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56.2B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.3B USD
-11%

Bergenbio ASA
Glance View

Market Cap
52.5m NOK
Industry
Biotechnology

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

BGBIO Intrinsic Value
Not Available
B
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-16 424.8%
=
Net Income
-139.3m
/
Revenue
848k
What is the Net Margin of Bergenbio ASA?

Based on Bergenbio ASA's most recent financial statements, the company has Net Margin of -16 424.8%.

Back to Top